TY - JOUR T1 - Clonal inactivation of telomerase promotes accelerated stem cell differentiation JF - bioRxiv DO - 10.1101/2021.04.28.441728 SP - 2021.04.28.441728 AU - Kazuteru Hasegawa AU - Yang Zhao AU - Alina Garbuzov AU - M. Ryan Corces AU - Lu Chen AU - Peggie Cheung AU - Yuning Wei AU - Howard Y. Chang AU - Steven E. Artandi Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/06/05/2021.04.28.441728.abstract N2 - Telomerase is intimately associated with stem cells and upregulated in cancer, where it serves essential roles through its catalytic action in elongating telomeres, nucleoprotein caps that protect chromosome ends1. Overexpression of the telomerase reverse transcriptase (TERT) enhances cell proliferation through telomere-independent means, yet definitive evidence for such a direct role in stem cell function has yet to be revealed through loss-of-function studies. Here, we show that conditional deletion of TERT in spermatogonial stem cells (SSCs) markedly impairs competitive clone formation. Using lineage-tracing from the Tert locus, we find that TERT-expressing SSCs yield long-lived clones, but that selective TERT-inactivation in SSCs causes accelerated stem cell differentiation thereby disrupting clone formation. This requirement for TERT in clone formation is bypassed by expression of a catalytically inactive TERT transgene and occurs independently of the canonical telomerase complex. TERT inactivation induces a genome-wide reduction in open chromatin evident in purified SSCs, but not in committed progenitor cells. Loss of TERT causes reduced activity of the MYC oncogene and transgenic expression of MYC in TERT-deleted SSCs efficiently rescues clone formation. These data reveal a required catalytic activity-independent role for TERT in preventing stem cell differentiation, forge a genetic link between TERT and MYC and suggest new means by which TERT may promote tumorigenesis.Competing Interest StatementH.Y.C. is a co-founder of Accent Therapeutics, Boundless Bio, and an advisor to 10x Genomics, Arsenal Biosciences, and Spring Discovery. ER -